CHM 0.00% 1.4¢ chimeric therapeutics limited

Ann: First phase 1B trial of NK cells with IL-2 & Vactosertib

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. lightbulb Created with Sketch. 851
 
watchlist Created with Sketch. Add CHM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.